PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24138103-6	2014	Thiorphan, captopril, and omapatrilat all enhanced the vasodilator response to bradykinin (all P < 0.01).	omapatrilat	26-37	kininogen 1	Homo sapiens	79-89	
26992459-10	2016	Omapatrilat blocked three pathways that break down bradykinin, leading to high rates of angioedema.	omapatrilat	0-11	kininogen 1	Homo sapiens	51-61	
24138103-9	2014	CONCLUSIONS: NEP inhibition with thiorphan modestly augmented the vasodilator action of bradykinin, but did not potentiate the response to adrenomedullin; dual ACE and NEP inhibition with omapatrilat, as expected, markedly augmented the response to bradykinin and also potentiated the effect of adrenomedullin.	omapatrilat	188-199	kininogen 1	Homo sapiens	249-259	
17170519-5	2006	Bradykinin levels in contrast were increased by MPCM and treatment with omapatrilat further augmented levels.	omapatrilat	72-83	kininogen 1	Homo sapiens	0-10	
18084312-1	2008	BACKGROUND AND PURPOSE: Inhibition of bradykinin metabolizing enzymes (BMEs) can cause acute angioedema, as demonstrated in a recent clinical trial in patients administered the antihypertensive, omapatrilat.	omapatrilat	195-206	kininogen 1	Homo sapiens	38-48	
17170519-6	2006	Co-incubation with the bradykinin B2 receptor antagonist HOE 140 attenuated the omapatrilat-induced lowering of fibronectin.	omapatrilat	80-91	kininogen 1	Homo sapiens	23-33	
12487427-0	2002	Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and omapatrilat.	omapatrilat	124-135	kininogen 1	Homo sapiens	17-27	
15162074-0	2004	Omapatrilat limits infarct size and lowers the threshold for induction of myocardial preconditioning through a bradykinin receptor-mediated mechanism.	omapatrilat	0-11	kininogen 1	Homo sapiens	111-121	
15162074-2	2004	Through simultaneous inhibition of neutral endopeptidase and angiotensin converting enzyme, omapatrilat prevents enzymatic degradation of bradykinin.	omapatrilat	92-103	kininogen 1	Homo sapiens	138-148	
15162074-3	2004	The aim of this study was to investigate if omapatrilat, through its ability to augment bradykinin levels, can augment a subthreshold IPC stimulus (Sub-IPC) and to compare the action of omapatrilat with the angiotensin-converting enzyme inhibitor, captopril.	omapatrilat	44-55	kininogen 1	Homo sapiens	88-98	
15162074-11	2004	We conclude that omapatrilat elicits cardioprotection via inhibition of bradykinin degradation and that dual inhibition of angiotensin-converting enzyme and neutral endopeptidase may have beneficial effects beyond standard angiotensin-converting enzyme inhibitor therapy in patients with acute coronary syndromes who are at risk of myocardial infarction.	omapatrilat	17-28	kininogen 1	Homo sapiens	72-82	
11588409-4	2001	Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin.	omapatrilat	34-45	kininogen 1	Homo sapiens	179-189	
11882619-8	2002	Arachidonic acid release by bradykinin from CHO/NEP-B(2) cells was also augmented by 100 nmol/L phosphoramidon or omapatrilat about 3-fold, and again, the inhibitors resensitized the desensitized B(2) receptor.	omapatrilat	114-125	kininogen 1	Homo sapiens	28-38	
11882619-11	2002	Consequently, omapatrilat could augment bradykinin effects on B(2), when either ACE or NEP is expressed close to receptor on cell membrane.	omapatrilat	14-25	kininogen 1	Homo sapiens	40-50	
11716803-0	2001	Omapatrilat: a new tool for understanding metabolism of bradykinin at the endothelium level.	omapatrilat	0-11	kininogen 1	Homo sapiens	56-66	
11046097-8	2000	Omapatrilat, a VPI, has a greater protective effect on BK metabolism than that of a pure ACE inhibitor.	omapatrilat	0-11	kininogen 1	Homo sapiens	55-57